The intervention showed no clear difference in second cancer‐ related mortality (low certainty).
The intervention showed no clear difference in cardiac disease‐ related mortality (low certainty).
The review found no eligible studies for this question.
The intervention probably leads to lower mortality sensitivity analysis (calculated instead of overall… (moderate certainty).
The intervention probably leads to lower relapse, progression or death (calculated instead of PFS) (moderate certainty).
The intervention showed no clear difference in infection‐ related mortality (low certainty).
The intervention showed no clear difference in second cancer‐ related mortality (low certainty).
The intervention showed no clear difference in cardiac disease‐ related mortality (low certainty).
The intervention showed no clear difference in complete response rate (low certainty).
The intervention may leads to higher mortality (calculated instead of overall survival) (low certainty).
The intervention showed no clear difference in relapse, progression or death (calculated instead of PFS) (low certainty).
Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in numbers of participants with at least 1 clinically significant… compared with higher transfusion threshold (20,000 or 30,000) (low certainty).
Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in number of participants with WHO Grade 3 or 4 bleeding up to 30 days… compared with higher transfusion threshold (20,000 or 30,000) (low certainty).
Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in time to first bleeding episode (days) compared with higher transfusion threshold (20,000 or 30,000) (low certainty).
Prophylactic platelet transfusion at threshold of 10,000 showed no clear difference in mortality from all causes up to 30 days from study entry compared with higher transfusion threshold (20,000 or 30,000) (low certainty).
The review found no eligible studies for this question.
Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in number of participants with at least 1 clinically significant… compared with prophylactic platelet transfusions with standard‐dose schedule (moderate certainty).
Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in number of participants with WHO grade 3 or 4 bleeding up to 30 days… compared with high‐dose schedule (low certainty).
Prophylactic platelet transfusions with low‐dose schedule showed no clear difference in mortality from all causes up to 30 days from study entry compared with high‐dose schedule (low certainty).